Amgen presented the data yesterday, fleshing out an earlier disclosure that the drug had achieved its main targets in five late-stage trials of 4,000 patients. Amgen is set to present data from the other two studies today.
Evolocumab is part of a new class of drugs called PCSK9 inhibitors, which block a protein that inhibits the ability of the liver to remove LDL from the blood.
Analysts have forecast that annual sales of each such drug could hit $3B or more. (PR)